Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

The Safety and Effectiveness of Antifungal Medications in the Management of Mucormycosis during the COVID-19 Pandemic

Author(s): Dhanya Jose, Krishna S. Nair, Murali Alagesan and Joseph M. Pappachan*

Volume 19, Issue 1, 2024

Published on: 10 May, 2023

Page: [3 - 7] Pages: 5

DOI: 10.2174/1574886318666230409145228

« Previous Next »
[1]
Aranjani JM, Manuel A, Abdul Razack HI, Mathew ST. COVID-19–associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India. PLoS Negl Trop Dis 2021; 15(11): e0009921.
[http://dx.doi.org/10.1371/journal.pntd.0009921] [PMID: 34793455]
[2]
Rodriguez-Morales AJ, Sah R, Millan-Oñate J, et al. COVID-19 associated mucormycosis: The urgent need to reconsider the indiscriminate use of immunosuppressive drugs. Ther Adv Infect Dis 2021; 8: 20499361211027065.
[http://dx.doi.org/10.1177/20499361211027065] [PMID: 34211710]
[3]
Patel A, Kaur H, Xess I, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect 2020; 26(7): 944.e9-944.e15.
[http://dx.doi.org/10.1016/j.cmi.2019.11.021] [PMID: 31811914]
[4]
Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLoS One 2021; 16(5): e0251170.
[http://dx.doi.org/10.1371/journal.pone.0251170] [PMID: 33956882]
[5]
Suvvari TK, Arigapudi N, Kandi VR, Kutikuppala LVS. Mucormycosis: A killer in the shadow of COVID-19. J Mycol Med 2021; 31(3): 101161.
[http://dx.doi.org/10.1016/j.mycmed.2021.101161] [PMID: 34146996]
[6]
Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol 2018; 56 (Suppl. 1): S93-S101.
[http://dx.doi.org/10.1093/mmy/myx101] [PMID: 29538730]
[7]
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19(12): e405-21.
[http://dx.doi.org/10.1016/S1473-3099(19)30312-3] [PMID: 31699664]
[8]
Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options. Ann Pharmacother 2016; 50(9): 747-57.
[http://dx.doi.org/10.1177/1060028016655425] [PMID: 27307416]
[9]
Directorate General Of Health Services, Ministry of Health & Family Welfare, Government of India. National leprosy Eradication program. Available from: https://dghs.gov.in/content/1349_3_NationalLeprosyEradicationProgramme.aspx
[10]
Stone NRH, Bicanic T, Salim R, Hope W. Liposomal Amphotericin B (AmBisome®): A review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs 2016; 76(4): 485-500.
[http://dx.doi.org/10.1007/s40265-016-0538-7] [PMID: 26818726]
[11]
Sun HY, Singh N. Mucormycosis: Its contemporary face and management strategies. Lancet Infect Dis 2011; 11(4): 301-11.
[http://dx.doi.org/10.1016/S1473-3099(10)70316-9] [PMID: 21453871]
[12]
Laniado-Laborín R, Cabrales-Vargas MN, Amphotericin B. Side effects and toxicity. Rev Iberoam Micol 2009; 26(4): 223-7.
[http://dx.doi.org/10.1016/j.riam.2009.06.003] [PMID: 19836985]
[13]
Yoshida I, Saito AM, Tanaka S, et al. Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever. Mycoses 2020; 63(8): 794-801.
[http://dx.doi.org/10.1111/myc.13100] [PMID: 32391919]
[14]
Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP. Therapy of mucormycosis. J Fungi 2018; 4(3): 90.
[http://dx.doi.org/10.3390/jof4030090] [PMID: 30065232]
[15]
Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011; 118(5): 1216-24.
[http://dx.doi.org/10.1182/blood-2011-03-316430] [PMID: 21622653]
[16]
Hof H. A new, broad-spectrum azole antifungal: Posaconazole? mechanisms of action and resistance, spectrum of activity. Mycoses 2006; 49(S1): 2-6.
[http://dx.doi.org/10.1111/j.1439-0507.2006.01295.x] [PMID: 16961575]
[17]
Gogineni H, So W, Mata K, Greene JN. Multidisciplinary approach in diagnosis and treatment of COVID-19-associated mucormycosis: A description of current reports. Egypt J Intern Med 2022; 34(1): 58.
[http://dx.doi.org/10.1186/s43162-022-00143-7] [PMID: 35911783]
[18]
Ellsworth M, Ostrosky-Zeichner L. Isavuconazole: Mechanism of action, clinical efficacy, and resistance. J Fungi 2020; 6(4): 324.
[http://dx.doi.org/10.3390/jof6040324] [PMID: 33260353]
[19]
Pal P, Chatterjee N, Ghosh S, et al. COVID associated mucormycosis: A study on the spectrum of clinical, biochemical and radiological findings in A series of ten patients. J Assoc Physicians India 2021; 69(10): 11-2.
[PMID: 34781648]
[20]
Bavadiya B, Bhatt J, Deshpande S, Mehta K, Raj R. Liver and renal function profile of mucormycosis cases receiving amphotericin B - A retrospective study. Apollo Medicine 2022; 19: 208-12.
[http://dx.doi.org/10.4103/am.am_86_22]
[21]
Garbino J, Uçkay I, Amini K, Puppo M, Richter M, Lew D. Absidia posttraumatic infection: Successful treatment with posaconazole. J Infect 2005; 51(3): e135-8.
[http://dx.doi.org/10.1016/j.jinf.2004.11.002] [PMID: 16230192]
[22]
Riad A, Shabaan AA, Issa J, et al. COVID-19-associated mucormycosis (CAM): Case-series and global analysis of mortality risk factors. J Fungi 2021; 7(10): 837.
[http://dx.doi.org/10.3390/jof7100837] [PMID: 34682258]
[23]
Pal R, Singh B, Bhadada SK, et al. COVID‐19‐associated mucormycosis: An updated systematic review of literature. Mycoses 2021; 64(12): 1452-9.
[http://dx.doi.org/10.1111/myc.13338] [PMID: 34133798]
[24]
Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: A report from the Seifem and Fungiscope registries. Haematologica 2013; 98(10): e127-30.
[http://dx.doi.org/10.3324/haematol.2012.083063] [PMID: 23716556]
[25]
Greenberg RN, Mullane K, van Burik JAH, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50(1): 126-33.
[http://dx.doi.org/10.1128/AAC.50.1.126-133.2006] [PMID: 16377677]
[26]
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005; 41(5): 634-53.
[http://dx.doi.org/10.1086/432579] [PMID: 16080086]

Rights & Permissions Print Cite
Article Metrics
17
2
© 2024 Bentham Science Publishers | Privacy Policy